US 2003/0199465 A1Published application

Novel polypeptides and nucleic acids encoding same

OwnerUriel M. Malyankar, Velizar T. Tchernev +10inventors

InventorsUriel M. Malyankar, Velizar T. Tchernev, Muralidhara Padigaru, Raymond J. Taupier JR., Kimberly A. Spytek, Xiaojia (Sasha) Guo, Steven K. Spaderna, Ferenc L. Boldog, Valerie Gerlach, Karen Ellerman, John R. MacDougall, Glennda Smithson

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

Claims79

Dependent claims

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26;
b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26;
d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
and
e) a fragment of any of a) through d).

7 more elements

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

a) a mature form of the amino acid sequence given SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or26;
b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26;
d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:
2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or 26 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed;
and
f) the complement of any of said nucleic acid molecules.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/131,409Filed 22 Apr 2002
Priority: 15 Feb 2000
Published: 23 Oct 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

C07K 14/47
From vertebrates: from mammals
C07K 14/4702
Not used: regulators; Modulating activity
C07K 14/4748
Not used: tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
C07K 14/555
Cytokines; Lymphokines; Interferons: interferons [IFN]

Family

Application60/182,723Us provisional application · filed 15 Feb 2000
Application60/182,733Us provisional application · filed 15 Feb 2000
Application60/182,724Us provisional application · filed 15 Feb 2000
Application60/183,896Us provisional application · filed 22 Feb 2000
Application60/184,497Us provisional application · filed 23 Feb 2000
Application60/184,482Us provisional application · filed 23 Feb 2000
Application60/184,275Us provisional application · filed 23 Feb 2000
Application60/184,744Us provisional application · filed 24 Feb 2000
Application60/197,083Us provisional application · filed 13 Apr 2000
Application60/215,855Us provisional application · filed 3 Jul 2000
Application60/224,157Us provisional application · filed 10 Aug 2000
Application60/233,405Us provisional application · filed 18 Sep 2000
Application60/236,060Us provisional application · filed 27 Sep 2000
Application60/259,414Us provisional application · filed 2 Jan 2001
Application60/262,454Us provisional application · filed 18 Jan 2001
Application09/783,429Continuation · filed 14 Feb 2001
Application09/898,953Continuation · filed 3 Jul 2001
Application10/131,409Continuation · filed 22 Apr 2002
US 2003/0199465 A1This patent

From the US filing history. Foreign family members aren’t listed.